Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Detection of drug resistance in human ovarian carcinoma

  • 25 Accesses

  • 11 Citations


Drug-resistant cancer cells with the multidrug-resistance phenotype show overexpression ofP-glycoprotein, and we therefore tested carcinoma tissue from five patients with stage III or IV ovarian cancer forP-glycoprotein using 265/F4 and C 219 monoclonal antibodies, prepared against membrane glycoproteins in colchicine-resistant CHO cells. Using immunofluorescence and immunoblotting techniques, one of the tumors showed a positive reaction. Using the pcDR 1.5 clone we found that the same cancer tissue had elevated expression of the genes responsible for multidrug resistance. The demonstration of elevatedP-glycoprotein in ovarian carcinomas indicates thatP-glycoprotein overexpression is not limited to experimental tumor models.

This is a preview of subscription content, log in to check access.


  1. 1.

    Beck WT, Müller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in vinca alkaloid resistant human leukemia lymphoblasts. Cancer Res 39:2070–2076

  2. 2.

    Bell DR, Gerlach JH, Kartner N, Buick RN, Ling V (1985) Detection ofP-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol, 3:311–315

  3. 3.

    Biedler JL, Chang T, Meyers MB, Peterson RHF, Sprengler, BA (1983) Drug resistance in Chinese hamster lung and mouse tumor cells. Cancer Treat Rep 67:859–867

  4. 4.

    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

  5. 5.

    Danø K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466–483

  6. 6.

    Fairbanks G, Steck TL, Wallach DFH (1971) Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 10:2606–2617

  7. 7.

    Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM (1987) Glycoprotein in human sarcoma: evidence for multidrug resistance J Clin Oncol 5:1452–1460

  8. 8.

    Gros P, Croop J, Roninson I, Varshavsky A, Housman DE (1986) Isolation and characterization of DNA sequences amplified in multidrug resistant hamster cells. Proc Natl Acad Sci USA 83:337–341

  9. 9.

    Gros P, Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug-resistance. Nature 323:728–731

  10. 10.

    Group For Sensitivity Testing of Tumors (KSST) (1981) In vitro short-term test to determine the resistance of human tumors in chemotherapy. Cancer 48:2127–2135

  11. 11.

    Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 55:152–162

  12. 12.

    Kartner N, Evernden-Porelle D, Bradley, G, Ling V (1985) Detection ofP-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316:820–823

  13. 13.

    Lathan B, Edwards DP, Dressler LG, Von Hoff DD, McGuire WL (1985) Immunological detection of Chinese hamster ovary cells expressing a multidrug resistance phenotype. Cancer Res 45:5064–5069

  14. 14.

    Ma DDF, Davey RA, Harman DH, Isbister JP, Scurr RD, Mackertich SM, Dowden G, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet I:135–137

  15. 15.

    Mattern J, Volm M (1982) Clinical relevance of predictive, tests for cancer chemotherapy. Cancer Treat Rev 9:267–298

  16. 16.

    Riordan JR, Ling V (1979) Purification ofP-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability.. J Biol Chem 254:12701–12705

  17. 17.

    Riordan JR, Ling V (1985) Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 28:51–75

  18. 18.

    Salmon SE, Hamburger AW, Soehnlein B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer agents. N Engl J Med 298:1321–1327

  19. 19.

    Siegfried JA, Kennedy KA, Sartorelli AC, Tritton TR (1983) The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. J Biol Chem 258:339–343

  20. 20.

    Skovsgaard T (1978) Carrier-mediated transport of daunorubicin-adriamycin and rubidazone in Ehrlich ascites tumor cells. Biochem Pharmacol 27:1221–1227

  21. 21.

    Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354

  22. 22.

    Volm M, Wayss K, Kaufmann M, Mattern J (1979) Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15:983–993

  23. 23.

    Volm M, Bak M, Mattern J (1988) Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins. Arzneimittelforschung. 38:1189–1193

  24. 24.

    Volm M, Bak M, Efferth Th, Lathan B, Mattern J (1988) Immunocytochemical detection of a resistance associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res 8:531–536

  25. 25.

    Volm M, Bak M, Efferth Th, Mattern J (1988) Induced multidrug-resistance in murine sarcoma 180 cells in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins. Anticancer Res 8:1169–1178

  26. 26.

    Wheeler C, Rader R, Kessel D (1982) Membrane alterations associated with progressive adriamycin resistance. Biochem Pharmacol 31:2691–2693

Download references

Author information

Correspondence to M. Volm.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Volm, M., Efferth, T., Bak, M. et al. Detection of drug resistance in human ovarian carcinoma. Arch Gynecol Obstet 244, 123–128 (1989). https://doi.org/10.1007/BF00931383

Download citation

Key words

  • Human ovarian carcinoma
  • Multidrug resistance
  • P-glycoprotein
  • Monoclonal antibodies